A Study of ERY974 in Patient With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This is the open label, multicenter Phase 1 study which consists of a dose escalation to
determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary
evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican
3 positive advanced solid tumors until unacceptable toxicity or disease progression.